Rethink on blood plasma treatment for COVID-19
US health officials say the emerging data shows on the therapy is weak
The emergency approval of blood plasma as a potential COVID-19 treatment by the US Food and Drug Administration has now been put on hold, the New York Times has reported, citing two senior administration officials.
A group of top federal health officials including the government’s top infectious disease expert, Dr Anthony Fauci, have argued that the emerging data on the treatment is too weak, the report says.
